Sangamo to reclaim hemophilia A therapy rights post Pfizer termination

(Reuters) – Sangamo Therapeutics said on Monday it would regain full rights to its hemophilia A gene therapy after co-development partner Pfizer terminated the agreement.

(Reporting by Puyaan Singh in Bengaluru; Editing by Mohammed Safi Shamsi)